Literature DB >> 27313729

Construction of Ang2-siRNA chitosan magnetic nanoparticles and the effect on Ang2 gene expression in human malignant melanoma cells.

Zhao-Liang Liu1, Cai-Lian You1, Biao Wang1, Jian-Hong Lin1, Xue-Feng Hu2, Xiu-Ying Shan1, Mei-Shui Wang1, Hou-Bing Zheng1, Yan-Ding Zhang2.   

Abstract

The aim of the present study was to construct angiopoietin-2 (Ang2)-small interfering (si)RNA chitosan magnetic nanoparticles and to observe the interference effects of the nanoparticles on the expression of the Ang2 gene in human malignant melanoma cells. Ang2-siRNA chitosan magnetic nanoparticles were constructed and transfected into human malignant melanoma cells in vitro. Red fluorescent protein expression was observed, and the transfection efficiency was analyzed. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to assess the inhibition efficiency of Ang2 gene expression. Ang2-siRNA chitosan magnetic nanoparticles were successfully constructed, and at a mass ratio of plasmid to magnetic chitosan nanoparticles of 1:100, the transfection efficiency into human malignant melanoma cells was the highest of the ratios assessed, reaching 61.17%. RT-qPCR analysis showed that the magnetic chitosan nanoparticles effectively inhibited Ang2 gene expression in cells, and the inhibition efficiency reached 59.56% (P<0.05). Ang2-siRNA chitosan magnetic nanoparticles were successfully constructed. The in vitro studies showed that the nanoparticles inhibited Ang2 gene expression in human malignant melanoma tumor cells, which laid the foundation and provided experimental evidence for additional future in vivo studies of intervention targeting malignant melanoma tumor growth in nude mice.

Entities:  

Keywords:  RNA interference; angiopoietin 2; chitosan magnetic nanoparticles; malignant melanoma

Year:  2016        PMID: 27313729      PMCID: PMC4888209          DOI: 10.3892/ol.2016.4539

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 2.  Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy.

Authors:  Sania Mansouri; Patrick Lavigne; Karin Corsi; Mohamed Benderdour; Eric Beaumont; Julio C Fernandes
Journal:  Eur J Pharm Biopharm       Date:  2004-01       Impact factor: 5.571

3.  The effect of the degree of chitosan deacetylation on the efficiency of gene transfection.

Authors:  Tina Kiang; Jie Wen; Huay Wen Lim; Kam W Leong
Journal:  Biomaterials       Date:  2004-10       Impact factor: 12.479

4.  Gene electrotransfer of siRNAs against CD146 inhibits migration and invasion of human malignant melanoma cells SK-MEL28.

Authors:  V Todorovic; G Sersa; M Cemazar
Journal:  Cancer Gene Ther       Date:  2013-02-01       Impact factor: 5.987

Review 5.  Nonviral gene transfer as a tool for studying transcription regulation of xenobiotic metabolizing enzymes.

Authors:  Barbara Bonamassa; Dexi Liu
Journal:  Adv Drug Deliv Rev       Date:  2010-08-14       Impact factor: 15.470

6.  [Personalized therapy concepts for malignant melanoma].

Authors:  M Schlaak; N Kreuzberg; C Mauch; P Kurschat
Journal:  Internist (Berl)       Date:  2013-02       Impact factor: 0.743

7.  Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy.

Authors:  Eriya Kenjo; Tomohiro Asai; Norihito Yonenaga; Hidenori Ando; Takayuki Ishii; Kentaro Hatanaka; Kosuke Shimizu; Yugo Urita; Takehisa Dewa; Mamoru Nango; Hideo Tsukada; Naoto Oku
Journal:  Biol Pharm Bull       Date:  2013       Impact factor: 2.233

Review 8.  Surgical treatment of malignant melanoma.

Authors:  Richard Essner
Journal:  Surg Clin North Am       Date:  2003-02       Impact factor: 2.741

9.  From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.

Authors:  Stefan Stein; Simone Scholz; Joachim Schwäble; Mohammed A Sadat; Ute Modlich; Stephan Schultze-Strasser; Margarita Diaz; Linping Chen-Wichmann; Uta Müller-Kuller; Christian Brendel; Raffaele Fronza; Kerstin B Kaufmann; Sonja Naundorf; Nancy K Pech; Jeffrey B Travers; Juan D Matute; Robert G Presson; George E Sandusky; Hana Kunkel; Eva Rudolf; Adelina Dillmann; Christof von Kalle; Klaus Kühlcke; Christopher Baum; Axel Schambach; Mary C Dinauer; Manfred Schmidt; Manuel Grez
Journal:  Hum Gene Ther Clin Dev       Date:  2013-06       Impact factor: 5.032

10.  Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.

Authors:  Jonathan Oliner; Hosung Min; Juan Leal; Dongyin Yu; Shashirekha Rao; Edward You; Xiu Tang; Haejin Kim; Susanne Meyer; Seog Joon Han; Nessa Hawkins; Robert Rosenfeld; Elyse Davy; Kevin Graham; Frederick Jacobsen; Shirley Stevenson; Joanne Ho; Qing Chen; Thomas Hartmann; Mark Michaels; Michael Kelley; Luke Li; Karen Sitney; Frank Martin; Ji-Rong Sun; Nancy Zhang; John Lu; Juan Estrada; Rakesh Kumar; Angela Coxon; Stephen Kaufman; James Pretorius; Sheila Scully; Russ Cattley; Marc Payton; Steve Coats; Linh Nguyen; Binodh Desilva; Anthony Ndifor; Isaac Hayward; Robert Radinsky; Tom Boone; Richard Kendall
Journal:  Cancer Cell       Date:  2004-11       Impact factor: 31.743

View more
  2 in total

1.  Effect of Chitosan Magnetic Nanoparticles Loaded with Ang2-siRNA Plasmids on the Growth of Melanoma Xenografts in Nude Mice.

Authors:  Xiuying Shan; Wenjun Yu; Xuejun Ni; Tingting Xu; Chen Lei; Zhaoliang Liu; Xuefeng Hu; Yanding Zhang; Beichen Cai; Biao Wang
Journal:  Cancer Manag Res       Date:  2020-08-20       Impact factor: 3.989

2.  Targeting of angiopoietin 2-small interfering RNA plasmid/chitosan magnetic nanoparticles in a mouse model of malignant melanoma in vivo.

Authors:  Xiu-Ying Shan; Ting-Ting Xu; Zhao-Liang Liu; Xue-Feng Hu; Yan-Ding Zhang; Shu-Zhong Guo; Biao Wang
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.